FirstWord

The oral CGRP inhibitor is the first of its class to successfully reduce migraine days in adults with menstrual migraine.

Plump will step down in June 2027.

Patients already randomised in the Phase II/III trial can continue to receive opakalim, a selective Kv7.2/7.3 potassium channel activator.

Since September last year, an additional £2 billion ($2.7 billion) has been invested in the UK, according to the Association of the British Pharmaceutical Industry.

The biotech will advance its ruvonoflast into a Phase III peripheral artery disease trial after positive mid-stage inflammation data.

FirstWord spoke with University College London’s Adam Ioannou about detailed Phase III CARDIO-TTransform data for AZ and Ionis' eplontersen, and what impact the failed study will have on use of TTR silencers and stabilisers to treat ATTR-CM.

SAN DIEGO--(BUSINESS WIRE)-- Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the acceptance of an abstract f...

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposiu...

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commerci...

Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo modelsCHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ...